Becton Dickinson and
BDX | NYSE
$199.41
+$1.53 (+0.77%)
Nov 2, 2026, 1:37 PM ET · Market open
Company Profile
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Thomas E. Polen Jr. | President, Chief Executive Officer & Chairman |
| Denise Fleming | Executive Vice President & Chief Information Officer |
| Elizabeth McCombs | Executive Vice President & Chief Technology Officer |
| Manish Sinha | Executive Vice President & Chief People Officer |
| Meera Gopalakrishnan | Senior VP & Global Chief Marketing Officer |
| Vitor Roque | Executive Vice President & Chief Financial Officer |
| Carla Burigatto | Senior Vice President & Chief Communications Officer |
| Joseph Smith | Senior Vice President & Chief Scientific Officer |
| Lanesha T. Minnix | Executive Vice President & General Counsel |
| Michael C. Feld | Executive VP & Chief Revenue Officer |
| Michael Garrison | Executive VP & President of Medical Segment and BioPharma Systems Segments |
| Shawn C. Bevec | Senior Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 29, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Aug 27, 2026 | 4 | Filing |
| Aug 24, 2026 | 4 | Filing |
| Aug 14, 2026 | 4 | Filing |
| Aug 12, 2026 | 4 | Filing |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 06, 2026 | 4 | Filing |
| Aug 06, 2026 | 4 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
Becton Dickinson and
| Country | United States |
| IPO Date | Feb 21, 1973 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 72,000 |
| CEO | Thomas E. Polen Jr. |
Contact Details
1 Becton Drive Franklin Lakes,
New Jersey 07417-1880 United States
Stock Details
| Ticker Symbol | BDX |
| Exchange | NYSE |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000010795 |
| CUSIP Number | 075887109 |
| ISIN Number | US0758871091 |
| SIC Code | 3841 |
Recent News
- 4 days ago / zacks.comBecton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?
- 5 days ago / prnewswire.comBD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
- 7 days ago / seekingalpha.comFirst Eagle U.S. Value Fund Q3 2026 Portfolio Review
- 11 days ago / zacks.comBDX Stock Gains 25.5% in Six Months: What's Behind the Rally?
- 18 days ago / zacks.comBD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients
- 24 days ago / zacks.comWill Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?
- 25 days ago / prnewswire.comBD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- 26 days ago / zacks.comBDX Expands U.S. Manufacturing With $19B Healthcare Investment
- 26 days ago / prnewswire.comBD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- 27 days ago / benzinga.comBecton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing
Add to Watchlist
Select watchlists to add or remove BDX